Abound Wealth Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Abound Wealth Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5	Closed	-$124	–	1412
2026 Q1	$124	Hold	5	–	–	﹤0.01%	1368
2025 Q4	$117	Hold	5	–	–	﹤0.01%	1360
2025 Q3	$99	Hold	5	–	–	﹤0.01%	1308
2025 Q2	$109	Sell	5 -1	-17%	-$24	﹤0.01%	1238
2025 Q1	$146	Sell	6 -4	-40%	-$90	﹤0.01%	1104
2024 Q4	$209	Hold	10	–	–	﹤0.01%	1044
2024 Q3	$199	Sell	10 -2	-17%	-$37	﹤0.01%	1165
2024 Q2	$186	Sell	12 -5	-29%	-$78	﹤0.01%	1117
2024 Q1	$271	Hold	17	–	–	﹤0.01%	1167
2023 Q4	$286	Buy	+17	New	+$232	﹤0.01%	1182

Other funds holding CPRX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

LTAS

Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

EWM

Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return

OLA

Oliver Luxxe Assets Gladstone, New Jersey $680M AUM 47.51% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Abound Wealth Management's CPRX Position: Q2 2026 in Review

Abound Wealth Management sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 5 shares — an estimated $124 sold.

Abound Wealth Management first reported a position in CPRX in Q4 2023 and held it in 10 quarters. The position peaked at $286 in Q4 2023. 36 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Abound Wealth Management reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
Abound Wealth Management sold 5 Catalyst Pharmaceutical shares in Q2 2026, an estimated $124.
Abound Wealth Management first reported a position in Catalyst Pharmaceutical in Q4 2023 and held it in 10 quarters.
Abound Wealth Management's Catalyst Pharmaceutical position peaked at $286 in Q4 2023.
36 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Abound Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.